Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares
THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER COUNTRY WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS UNDER SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has, in connection with the preferential rights issue announced on 22 February 2024, prepared a prospectus (the "Prospectus") which today has been approved and registered by the Swedish Financial Supervisory Authority.
Publication of Prospectus
The Prospectus has today, 27 March 2024, been approved and registered with the Swedish Financial Supervisory Authority. The Prospectus refers to an invitation to subscribe for shares as a result of the rights issue published in a press release on 22 February 2024 (the "Rights Issue"). The Prospectus, containing complete terms and conditions, instructions and application forms for the Rights issue are available on the Company's website (www.abliva.com) and on Hagberg & Aneborn Fondkommission's website (www.hagberganeborn.se). The prospectus will also be available on Finansinspektionen's website (www.fi.se).
The rights issue in summary
-
Shareholders in Abliva receive one (1) subscription right per share held on the record date of 28 March 2024
-
Eleven (11) subscription rights entitle to subscribe for three (3) new shares
-
The subscription price is SEK 0.16 per share
-
Trading in subscription rights takes place during the period 3 - 12 April 2024
-
The subscription period runs during the period 3 - 17 April 2024
The rights issue is 100 percent covered by subscription and guarantee commitments. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 46 million before transaction costs which is estimated to amount to approximately SEK 6.5 million (of which up to approximately SEK 3.3 million is underwriting fees). For further information on the Rights Issue, please refer to the published prospectus.
Advisors
Hagberg & Aneborn Fondkommission AB is the sole global coordinator and bookrunner in connection with the Rights Issue. Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Rights Issue.
Abliva - Delivering mitochondrial health
Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
Important information
Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and persons in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Abliva in any jurisdiction.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland, the United States, or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.
This press release is not a prospectus.
|
Abliva AB